[go: up one dir, main page]
More Web Proxy on the site http://driver.im/

MXPA05007181A - Cristales de la hormona de crecimiento humano y metodos para prepararlos. - Google Patents

Cristales de la hormona de crecimiento humano y metodos para prepararlos.

Info

Publication number
MXPA05007181A
MXPA05007181A MXPA05007181A MXPA05007181A MXPA05007181A MX PA05007181 A MXPA05007181 A MX PA05007181A MX PA05007181 A MXPA05007181 A MX PA05007181A MX PA05007181 A MXPA05007181 A MX PA05007181A MX PA05007181 A MXPA05007181 A MX PA05007181A
Authority
MX
Mexico
Prior art keywords
growth hormone
human growth
crystals
methods
preparing
Prior art date
Application number
MXPA05007181A
Other languages
English (en)
Inventor
Paul Benjamin Simeone
Original Assignee
Altus Pharmaceuticals Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Altus Pharmaceuticals Inc filed Critical Altus Pharmaceuticals Inc
Publication of MXPA05007181A publication Critical patent/MXPA05007181A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/575—Hormones
    • C07K14/61—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • A61K38/22—Hormones
    • A61K38/27—Growth hormone [GH], i.e. somatotropin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P15/00—Drugs for genital or sexual disorders; Contraceptives
    • A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/02—Drugs for dermatological disorders for treating wounds, ulcers, burns, scars, keloids, or the like
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/08—Drugs for skeletal disorders for bone diseases, e.g. rachitism, Paget's disease
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P5/00—Drugs for disorders of the endocrine system
    • A61P5/06—Drugs for disorders of the endocrine system of the anterior pituitary hormones, e.g. TSH, ACTH, FSH, LH, PRL, GH
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Endocrinology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Reproductive Health (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Virology (AREA)
  • Communicable Diseases (AREA)
  • Dermatology (AREA)
  • Oncology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Rheumatology (AREA)
  • Urology & Nephrology (AREA)
  • Diabetes (AREA)
  • Gynecology & Obstetrics (AREA)
  • Pregnancy & Childbirth (AREA)
  • AIDS & HIV (AREA)
  • Immunology (AREA)
  • Epidemiology (AREA)

Abstract

La presente invencion se relaciona con cristales de liberacion prolongada, estables, de la hormona de crecimiento humano o un derivado de la hormona de crecimiento humano y las composiciones o formulaciones que comprenden estos cristales. La invencion tambien proporciona los metodos para producir esos cristales y composiciones. La invencion tambien proporciona los metodos para el tratamiento de un individuo que padece trastornos asociados con la deficiencia de la hormona de crecimiento humano o que se mejoran mediante el tratamiento con la hormona de crecimiento humano utilizando esos cristales y composiciones o formulaciones.
MXPA05007181A 2002-12-31 2003-12-31 Cristales de la hormona de crecimiento humano y metodos para prepararlos. MXPA05007181A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US43751902P 2002-12-31 2002-12-31
US51704203P 2003-11-03 2003-11-03
PCT/US2003/041545 WO2004060310A2 (en) 2002-12-31 2003-12-31 Human growth hormone crystals and methods for preparing them

Publications (1)

Publication Number Publication Date
MXPA05007181A true MXPA05007181A (es) 2006-04-07

Family

ID=32717908

Family Applications (1)

Application Number Title Priority Date Filing Date
MXPA05007181A MXPA05007181A (es) 2002-12-31 2003-12-31 Cristales de la hormona de crecimiento humano y metodos para prepararlos.

Country Status (12)

Country Link
US (1) US9376479B2 (es)
EP (2) EP1581251B1 (es)
JP (2) JP4686361B2 (es)
KR (1) KR20050090430A (es)
AU (2) AU2003303646B2 (es)
BR (1) BR0317888A (es)
CA (1) CA2512052C (es)
DK (1) DK1581251T3 (es)
MX (1) MXPA05007181A (es)
RU (1) RU2357750C2 (es)
SG (1) SG176314A1 (es)
WO (1) WO2004060310A2 (es)

Families Citing this family (28)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CA2512001A1 (en) * 2002-12-31 2004-07-22 Altus Pharmaceuticals Inc. Complexes of protein crystals and ionic polymers
DK1581251T3 (da) 2002-12-31 2016-06-27 Althea Tech Inc Krystaller af humant væksthormon og fremgangsmåder til fremstilling deraf
US20090029911A1 (en) * 2003-09-25 2009-01-29 Ashley Martin Williams Liquid Human Growth Hormone Formulation Containing Polyethylene Glycol
US8728525B2 (en) 2004-05-12 2014-05-20 Baxter International Inc. Protein microspheres retaining pharmacokinetic and pharmacodynamic properties
EP1888117A1 (en) * 2005-05-25 2008-02-20 Novo Nordisk A/S Stabilized polypeptide formulations
EP1888118B1 (en) 2005-05-25 2016-08-17 Novo Nordisk A/S Polypeptide formulations stabilized with ethylenediamine
CA2634053A1 (en) * 2005-12-23 2007-07-05 Altus Pharmaceuticals Inc. Compositions comprising polycation-complexed protein crystals and methods of treatment using them
US9249407B2 (en) 2006-02-03 2016-02-02 Opko Biologics Ltd. Long-acting coagulation factors and methods of producing same
US10351615B2 (en) 2006-02-03 2019-07-16 Opko Biologics Ltd. Methods of treatment with long-acting growth hormone
EP2647712A3 (en) 2006-08-04 2013-11-20 Baxter International Inc Microsphere-based composition for preventing and/or reversing new-onset autoimmune diabetes
CA2661521C (en) * 2006-08-31 2016-04-12 Novartis Ag Pharmaceutical compositions comprising hgh for oral delivery
WO2008076819A2 (en) * 2006-12-18 2008-06-26 Altus Pharmaceuticals Inc. Human growth hormone formulations
WO2008102469A1 (ja) * 2007-02-23 2008-08-28 Kwansei Gakuin Educational Foundation 蛋白質結晶化剤および蛋白質結晶化剤を用いた蛋白質結晶化方法
EP2078091A4 (en) * 2007-07-10 2010-09-01 Medimmune Llc CRYSTALS AND STRUCTURE OF THE VARIANT OF IGG FC HUMAN
EP2111871A1 (de) * 2008-04-26 2009-10-28 Sandoz AG Stabilisierte Flüssigformulierung
US8323615B2 (en) 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing multi-phasic dispersions
US8367427B2 (en) 2008-08-20 2013-02-05 Baxter International Inc. Methods of processing compositions containing microparticles
US8323685B2 (en) * 2008-08-20 2012-12-04 Baxter International Inc. Methods of processing compositions containing microparticles
RU2734236C2 (ru) * 2009-02-25 2020-10-13 Софткемо Фарма Корп. Композиции бендамустина и циклополисахарида
US9663778B2 (en) 2009-07-09 2017-05-30 OPKO Biologies Ltd. Long-acting coagulation factors and methods of producing same
WO2013075068A1 (en) 2011-11-18 2013-05-23 Regeneron Pharmaceuticals, Inc. Polymer protein microparticles
US20150158926A1 (en) * 2013-10-21 2015-06-11 Opko Biologics, Ltd. Long-acting polypeptides and methods of producing and administering same
EP3064213A4 (en) * 2013-10-28 2017-04-26 Terumo Kabushiki Kaisha Protein aqueous suspension
PL3310347T3 (pl) 2015-06-19 2021-12-27 Opko Biologics Ltd. Długo działające czynniki krzepnięcia i sposoby wytwarzania
MX2018004695A (es) * 2015-10-16 2019-03-14 Regeneron Pharma Composiciones de proteinas estables.
EP3481855B1 (en) 2016-07-11 2023-09-06 OPKO Biologics Ltd. Long-acting coagulation factor vii and methods of producing same
JP7104929B2 (ja) * 2017-07-24 2022-07-22 テルモ株式会社 医療用タンパク質とポリアミノ酸とを含む複合体の製造方法および医療用タンパク質とポリアミノ酸とを含む複合体
US11541105B2 (en) 2018-06-01 2023-01-03 The Research Foundation For The State University Of New York Compositions and methods for disrupting biofilm formation and maintenance

Family Cites Families (79)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2538018A (en) 1944-04-04 1951-01-16 Nordisk Insulinlab Crystalline product of insulin and alkaline protein and process of making it
GB643268A (en) 1944-04-04 1950-09-15 Nordisk Insulinlab Improved process for the preparation of prolonged effect insulin products
US4342832A (en) 1979-07-05 1982-08-03 Genentech, Inc. Method of constructing a replicable cloning vehicle having quasi-synthetic genes
US5618697A (en) 1982-12-10 1997-04-08 Novo Nordisk A/S Process for preparing a desired protein
IL79681A (en) 1985-08-12 1991-06-10 Int Minerals & Chem Corp Transition metal complexes of growth hormones and their prolonged release compositions
US4816568A (en) 1986-05-16 1989-03-28 International Minerals & Chemical Corp. Stabilization of growth hormones
US4917685A (en) 1986-05-16 1990-04-17 International Minerals & Chem. Corp. Delivery device for the administration of stabilized growth promoting hormones
PH23446A (en) 1986-10-20 1989-08-07 Novo Industri As Peptide preparations
US4853218A (en) 1987-02-24 1989-08-01 Schering Corporation Zinc-protamine-alpha interferon complex
ATE82506T1 (de) 1987-08-21 1992-12-15 Imcera Group Inc Stabilisierung von wachstumshormonen.
US5981485A (en) 1997-07-14 1999-11-09 Genentech, Inc. Human growth hormone aqueous formulation
US5096885A (en) 1988-04-15 1992-03-17 Genentech, Inc. Human growth hormone formulation
US5084350A (en) 1990-02-16 1992-01-28 The Royal Institution For The Advance Of Learning (Mcgill University) Method for encapsulating biologically active material including cells
NL9000634A (nl) 1990-03-20 1991-10-16 Catharina Ziekenhuis Stichting Suspensie-injectiepreparaat op waterbasis, werkwijze voor de bereiding daarvan en toepassing van dit preparaat voor pijnbestrijding.
DK0454044T3 (da) 1990-04-25 1996-04-22 Hoechst Ag Farmakologisk præparat indeholdende polyelektrolytkomplekser på mikropartikelform og mindst et virksomt stof
JPH0749440B2 (ja) 1990-06-04 1995-05-31 シェリング・コーポレーション インターフェロン アルファー２結晶の製造方法
US5780599A (en) 1990-07-13 1998-07-14 Novo Nordisk A/S Growth hormone crystals and a process for production of growth hormone crystals
DK168790D0 (es) * 1990-07-13 1990-07-13 Novo Nordisk As
WO1992011844A1 (en) 1991-01-03 1992-07-23 Alkermes Controlled Therapeutics, Inc. Stabilization of proteins by cationic biopolymers
DE4132005A1 (de) 1991-09-26 1993-04-01 Merck Patent Gmbh Kombination enthaltend wachstumsfaktoren und polyelektrolyte
DE10399015I1 (de) 1991-12-20 2012-05-03 Novo Nordisk As Stabilisierte pharmazeutische formulierung, die wachstumshormon und histidin enthält
US5849700A (en) * 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
US6022858A (en) 1991-12-20 2000-02-08 Novo Nordisk A/S Pharmaceutical formulation of human-growth hormone pretreated with zinc salt
US5849704A (en) 1991-12-20 1998-12-15 Novo Nordisk A/S Pharmaceutical formulation
US5198422A (en) 1992-06-11 1993-03-30 Smithkline Beecham Corporation Stabilized somatotropin for parenteral administration
ES2153385T5 (es) 1992-07-31 2008-09-01 Genentech, Inc. Composicion acuosa a base de hormona del crecimiento humana.
SE9302278D0 (sv) 1992-10-28 1993-07-02 Kabi Pharmacia Ab Growth hormone
CA2150803C (en) 1992-12-02 2006-01-31 Henry Auer Controlled release growth hormone containing microspheres
RU2143889C1 (ru) 1993-02-23 2000-01-10 Генентек, Инк. Способ стабилизации полипептида, способы получения композиций полипептида и композиции
US6284727B1 (en) 1993-04-07 2001-09-04 Scios, Inc. Prolonged delivery of peptides
DK72793D0 (da) 1993-06-21 1993-06-21 Novo Nordisk As Nyt produkt
US6087324A (en) 1993-06-24 2000-07-11 Takeda Chemical Industries, Ltd. Sustained-release preparation
US5439643A (en) 1993-11-03 1995-08-08 Liebert; Richard T. Method and apparatus for terminal sterilization
US5610134A (en) 1994-04-15 1997-03-11 Genentech, Inc. Treatment of congestive heart failure
US5582591A (en) 1994-09-02 1996-12-10 Delab Delivery of solid drug compositions
CN1157562A (zh) 1994-09-09 1997-08-20 武田药品工业株式会社 含有一种肽金属盐的缓释制剂
US6004549A (en) 1994-12-14 1999-12-21 Schering Corporation Crystalline protein controlled release compositions
WO1996021460A1 (en) 1995-01-13 1996-07-18 Novo Nordisk A/S A stabilized pharmaceutical formulation comprising a growth hormone and x-lys
US5705482A (en) 1995-01-13 1998-01-06 Novo Nordisk A/S Pharmaceutical formulation
ZA96122B (en) 1995-01-13 1996-07-24 Novo Nordisk As A pharmaceutical formulation
US5788959A (en) * 1995-04-24 1998-08-04 University Of Maryland, Baltimore County Drug delivery device and method for employing the same
CA2224381A1 (en) 1995-06-27 1997-01-16 Takeda Chemical Industries, Ltd. Method of producing sustained-release preparation
CA2225963C (en) 1995-07-25 2008-02-05 Novartis Ag Transforming growth factor beta crystals
DE122006000003I2 (de) * 1995-09-21 2011-01-13 Genentech Inc Varianten des menschlichen wachstumshormons
US5972331A (en) 1995-12-22 1999-10-26 Schering Corporation Crystalline interferon alpha for pulmonary delivery and method for producing the same
US7276251B2 (en) 1997-04-01 2007-10-02 Lg Life Sciences, Ltd., Inc. Sustained-release composition of drugs encapsulated in microparticles of hyaluronic acid
US5932212A (en) 1996-05-24 1999-08-03 Altus Biologics, Inc. Crosslinked protein crystal formulations and their use as catalysts in organic solvents
EP0812856B1 (en) 1996-06-14 1999-09-29 Takeda Chemical Industries, Ltd. Method for removing N-terminal methionine
EP0819758B1 (en) 1996-07-16 2006-09-20 Archibald James Mixson Cationic vehicle: DNA complexes and their use in gene therapy
US5783556A (en) 1996-08-13 1998-07-21 Genentech, Inc. Formulated insulin-containing composition
US5968895A (en) 1996-12-11 1999-10-19 Praecis Pharmaceuticals, Inc. Pharmaceutical formulations for sustained drug delivery
DE69732306T2 (de) 1997-01-16 2006-01-12 Massachusetts Institute Of Technology, Cambridge Zubereitung von partikelhaltigen arzneimitteln zur inhalation
SE9700566D0 (sv) 1997-02-18 1997-02-18 Pharmacia & Upjohn Ab Modified proteins
DE69839563D1 (de) 1997-09-05 2008-07-10 Altus Pharmaceuticals Inc Kohlenhydrat-vernetzte glykoproteinkristalle
US6380357B2 (en) 1997-12-16 2002-04-30 Eli Lilly And Company Glucagon-like peptide-1 crystals
WO1999031137A1 (en) 1997-12-18 1999-06-24 Eli Lilly And Company Crystalline teriparatide
CO4970787A1 (es) 1997-12-23 2000-11-07 Lilly Co Eli Composiciones insolubles de insulina y derivados de insulina que controlan la glucosa sanguinea
US6541606B2 (en) 1997-12-31 2003-04-01 Altus Biologics Inc. Stabilized protein crystals formulations containing them and methods of making them
JP4965022B2 (ja) * 1998-04-27 2012-07-04 アルタス ファーマシューティカルズ インコーポレイテッド 安定化されたタンパク質結晶、それを含む処方物、およびそれを作製する方法
EP2311436A1 (en) 1998-04-27 2011-04-20 Altus Pharmaceuticals Inc. Stabilized protein crystals, formulations containing them and methods of making them
US6369118B1 (en) * 1998-09-09 2002-04-09 University Of Pittsburgh Biocompatible emulsifier
US7919119B2 (en) 1999-05-27 2011-04-05 Acusphere, Inc. Porous drug matrices and methods of manufacture thereof
JP4970678B2 (ja) 1999-06-10 2012-07-11 マックス−プランク−ゲゼルシャフト・ツア・フェルデルング・デア・ヴィッセンシャフテン・エー・ファオ 多層コーティングによる結晶のカプセル化
WO2001001964A2 (en) 1999-06-23 2001-01-11 Sedum Laboratories, Inc. Ionically formulated biomolecule microcarriers
EP1818409A1 (en) 1999-09-09 2007-08-15 CureVac GmbH Transfer of mRNAusing polycationic compounds
AT408721B (de) 1999-10-01 2002-02-25 Cistem Biotechnologies Gmbh Pharmazeutische zusammensetzung enthaltend ein antigen
US20020009491A1 (en) 2000-02-14 2002-01-24 Rothbard Jonathan B. Compositions and methods for enhancing drug delivery across biological membranes and tissues
US20040006473A1 (en) 2002-07-02 2004-01-08 Sbc Technology Resources, Inc. Method and system for automated categorization of statements
US6417237B1 (en) 2000-06-08 2002-07-09 The Board Of Trustees Of The University Of Illinois Macromolecular drug complexes and compositions containing the same
AU2001289079A1 (en) 2000-09-13 2002-03-26 Praecis Pharmaceuticals Incorporated Pharmaceutical compositions for sustained drug delivery
EP2186824A3 (en) 2000-12-13 2010-09-22 Eli Lilly & Company Chronic treatment regimen using glucagon-like insulinotropic peptides
AU2002256971B2 (en) 2000-12-28 2008-04-03 Altus Pharmaceuticals Inc. Crystals of whole antibodies and fragments thereof and methods for making and using them
EP1353685A2 (en) * 2000-12-29 2003-10-22 PBL Biomedical Laboratories Controlled release pharmaceutical systems
JP2004526589A (ja) 2001-01-09 2004-09-02 イーストマン コダック カンパニー インクジェットプリントヘッドの品質管理システムおよび方法
WO2003035099A1 (en) 2001-10-19 2003-05-01 Eli Lilly And Company Biphasic mixtures of glp-1 and insulin
US7741282B2 (en) 2001-11-13 2010-06-22 Genentech, Inc. ApO2 ligand/TRAIL formulations
WO2003086293A2 (en) 2002-04-09 2003-10-23 Taisho Pharmaceutical Co., Ltd. Pharmaceutical preparation for taste masking
CA2512001A1 (en) 2002-12-31 2004-07-22 Altus Pharmaceuticals Inc. Complexes of protein crystals and ionic polymers
DK1581251T3 (da) 2002-12-31 2016-06-27 Althea Tech Inc Krystaller af humant væksthormon og fremgangsmåder til fremstilling deraf

Also Published As

Publication number Publication date
WO2004060310A3 (en) 2004-12-09
EP1581251B1 (en) 2016-03-16
AU2010201961A1 (en) 2010-06-03
EP2460530A2 (en) 2012-06-06
DK1581251T3 (da) 2016-06-27
US20040209804A1 (en) 2004-10-21
EP1581251A2 (en) 2005-10-05
SG176314A1 (en) 2011-12-29
AU2003303646A1 (en) 2004-07-29
CA2512052C (en) 2016-06-21
JP4686361B2 (ja) 2011-05-25
KR20050090430A (ko) 2005-09-13
JP2006512416A (ja) 2006-04-13
RU2005124280A (ru) 2006-01-20
EP2460530A3 (en) 2012-08-29
RU2357750C2 (ru) 2009-06-10
BR0317888A (pt) 2005-12-06
WO2004060310A2 (en) 2004-07-22
US9376479B2 (en) 2016-06-28
JP2010209079A (ja) 2010-09-24
CA2512052A1 (en) 2004-07-22
EP1581251A4 (en) 2009-03-04
AU2003303646B2 (en) 2010-03-04
WO2004060310A8 (en) 2005-06-02

Similar Documents

Publication Publication Date Title
MXPA05007181A (es) Cristales de la hormona de crecimiento humano y metodos para prepararlos.
MY139296A (en) CRYSTALLINE ß2 ADRENERGIC RECEPTOR AGONIST
MXPA05012678A (es) Forma cristalina del agonista del receptor adrenergico beta2.
AU2003267203A8 (en) Method for administering thermotherapy to prevent the growth of tumors
GB0222495D0 (en) Compounds
HK1096673A1 (en) Compositions useful as inhibitors of protein kinases
TW200740765A (en) Crystalline modifications of pyraclostrobin
MXPA04001940A (es) Tratamiento para desordenes del sistema nervioso central.
TW200510325A (en) 2-acylamino-4-phenylthiazole derivatives, preparation thereof and therapeutic application thereof
MXPA04001334A (es) Materiales y metodos para promover la reparacion de tejido nervioso.
MY137053A (en) Pyrimidine derivatives and their use as cb2 modulators
SG145712A1 (en) Crystalline tumor necrosis factor receptor 2 polypeptides
HK1085140A1 (en) Pharmaceutical compositions and method of using levodopa and carbidopa
MXPA04003858A (es) Antagonistas de mch para el tratamiento de obesidad.
HRP20080689T3 (en) Imidazoline derivatives having cb1-antagonistic activity
WO2004039328A3 (en) Fludrocortisone treatment for hearing loss
TW200611695A (en) Pyrrolopyridine derivatives
TW200621765A (en) Substituted phenylaminothiazoles and their use
IL165558A0 (en) N-benzoylureidocinnamate derivatives method for production and use thereof
AU2003260436A1 (en) Pyrimidine compounds
SI1532131T1 (sl) Motilidne spojine
IL145122A0 (en) C16 unsaturated fp-selective prostaglandin analogs
MXPA05014184A (es) Utilizacion de acido hialuronico para la preparacion de composiciones para el tratamiento de aftas en la cavidad oral.
GB0326633D0 (en) Therapeutic agents
EP1441724B8 (en) Methods of increasing endogenous testosterone levels